Lynne Garrity-Ryan

1.4k total citations
25 papers, 1.1k citations indexed

About

Lynne Garrity-Ryan is a scholar working on Molecular Medicine, Infectious Diseases and Pharmacology. According to data from OpenAlex, Lynne Garrity-Ryan has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Medicine, 10 papers in Infectious Diseases and 9 papers in Pharmacology. Recurrent topics in Lynne Garrity-Ryan's work include Antibiotic Resistance in Bacteria (11 papers), Antimicrobial Resistance in Staphylococcus (10 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Lynne Garrity-Ryan is often cited by papers focused on Antibiotic Resistance in Bacteria (11 papers), Antimicrobial Resistance in Staphylococcus (10 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Lynne Garrity-Ryan collaborates with scholars based in United States, Romania and United Kingdom. Lynne Garrity-Ryan's co-authors include Amy Manley, Evan Tzanis, Joanne N. Engel, Barbara I. Kazmierczak, Judith N. Steenbergen, Stephen Villano, Sébastien Tanaka, Anita Das, Paul B. Eckburg and Surya Chitra and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Medicinal Chemistry.

In The Last Decade

Lynne Garrity-Ryan

24 papers receiving 1.1k citations

Peers

Lynne Garrity-Ryan

EPIDE

PHARM

Tatiana Bogdanovich United States

Fernando Docobo-Pérez Spain

An-Jing Kuo Taiwan

Guilène Barnaud France

André Birgy France

María Eugenia Pachón-Ibáñez Spain

María‐Isabel Morosini Spain

Apostolos Liakopoulos Netherlands

E. Espaze France

Qiwen Yang China

Tatiana Bogdanovich United States

Lynne Garrity-Ryan

522 ×1.1

391 ×1.2

275 ×0.9

EPIDE

237 ×0.8

278 ×1.1

PHARM

Citations per year, relative to Lynne Garrity-Ryan Lynne Garrity-Ryan (= 1×) peers Tatiana Bogdanovich

Countries citing papers authored by Lynne Garrity-Ryan

Since Specialization

Citations

This map shows the geographic impact of Lynne Garrity-Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynne Garrity-Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynne Garrity-Ryan more than expected).

Fields of papers citing papers by Lynne Garrity-Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynne Garrity-Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynne Garrity-Ryan. The network helps show where Lynne Garrity-Ryan may publish in the future.

Co-authorship network of co-authors of Lynne Garrity-Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of Lynne Garrity-Ryan. A scholar is included among the top collaborators of Lynne Garrity-Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynne Garrity-Ryan. Lynne Garrity-Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Torres, Antoni, Lynne Garrity-Ryan, Judith N. Steenbergen, et al.. (2021). Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. International Journal of Infectious Diseases. 104. 501–509. 11 indexed citations

Tanaka, Sébastien, et al.. (2021). Sub-growth-inhibitory concentrations of omadacycline inhibit Staphylococcus aureus haemolytic activity in vitro. JAC-Antimicrobial Resistance. 4(1). dlab190–dlab190. 1 indexed citations

Cornely, Oliver A., Thomas M. File, Lynne Garrity-Ryan, et al.. (2020). Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. International Journal of Antimicrobial Agents. 57(2). 106263–106263. 6 indexed citations

Tanaka, Sébastien, et al.. (2020). 1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro. Open Forum Infectious Diseases. 7(Supplement_1). S622–S623. 1 indexed citations

O’Riordan, William, Lynne Garrity-Ryan, Anita Das, et al.. (2019). Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. The Lancet Infectious Diseases. 19(10). 1080–1090. 73 indexed citations

Popescu, Monica, Ismail Mitha, William Nseir, et al.. (2019). Omadacycline for Community-Acquired Bacterial Pneumonia. New England Journal of Medicine. 380(6). 517–527. 171 indexed citations

Overcash, J. Scott, Lynne Garrity-Ryan, Judith N. Steenbergen, et al.. (2019). Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. Antimicrobial Agents and Chemotherapy. 63(5). 29 indexed citations

Sakoulas, George, Paul B. Eckburg, Amy Manley, et al.. (2019). 110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies. Open Forum Infectious Diseases. 6(Supplement_2). S86–S87. 1 indexed citations

Pai, Manjunath P., et al.. (2019). 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies. Open Forum Infectious Diseases. 6(Supplement_2). S316–S317. 1 indexed citations

10.

Darpö, Börje, Evan Tzanis, Lynne Garrity-Ryan, et al.. (2017). Cardiac Safety of Omadacycline in the IV/oral Phase 3 Acute Bacterial Skin and Skin Structure Infection (ABSSSI) and in the IV/oral Phase 3 Community-acquired Bacterial Pneumonia (CABP) Studies. Open Forum Infectious Diseases. 4(suppl_1). S544–S545. 4 indexed citations

11.

Popescu, Monica, Ismail Mitha, Andrzej Madej, et al.. (2017). A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study). Open Forum Infectious Diseases. 4(suppl_1). S543–S544. 11 indexed citations

12.

Berg, Jolene Kay, Evan Tzanis, Lynne Garrity-Ryan, et al.. (2017). Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. Antimicrobial Agents and Chemotherapy. 62(2). 38 indexed citations

13.

Tzanis, Evan, Lynne Garrity-Ryan, Stephen A. Bai, et al.. (2017). Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens. Antimicrobial Agents and Chemotherapy. 62(2). 32 indexed citations

14.

Garrity-Ryan, Lynne, Joan-Miquel Balada-Llasat, Victoria J. Bartlett, et al.. (2010). Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model. Infection and Immunity. 78(11). 4683–4690. 62 indexed citations

15.

Grier, Mark C., Lynne Garrity-Ryan, Victoria J. Bartlett, et al.. (2010). N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability. Bioorganic & Medicinal Chemistry Letters. 20(11). 3380–3383. 33 indexed citations

16.

Balachandran, Priya, et al.. (2007). The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T–mediated virulence. Journal of Clinical Investigation. 117(2). 419–427. 35 indexed citations

17.

Casaz, Paul, Lynne Garrity-Ryan, David McKenney, et al.. (2006). MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis. Microbiology. 152(12). 3643–3650. 30 indexed citations

18.

Garrity-Ryan, Lynne, Sasha H. Shafikhani, Priya Balachandran, et al.. (2003). The ADP Ribosyltransferase Domain of Pseudomonas aeruginosa ExoT Contributes to Its Biological Activities. Infection and Immunity. 72(1). 546–558. 65 indexed citations

19.

Geiser, Thomas, Barbara I. Kazmierczak, Lynne Garrity-Ryan, Michael A. Matthay, & Joanne N. Engel. (2001). Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair. Cellular Microbiology. 3(4). 223–236. 53 indexed citations

20.

Garrity-Ryan, Lynne, Barbara I. Kazmierczak, Robert Kowal, et al.. (2000). The Arginine Finger Domain of ExoT Contributes to Actin Cytoskeleton Disruption and Inhibition of Internalization ofPseudomonas aeruginosaby Epithelial Cells and Macrophages. Infection and Immunity. 68(12). 7100–7113. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact